In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption

Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme

(2012) U. Landmesser et al.   EUROPEAN HEART JOURNAL

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects

(2011) Eric J. Niesor et al.   ATHEROSCLEROSIS

Quantifying cholesterol synthesis in vivo using2H2O: enabling back-to-back studies in the same subject

(2011) Stephen F. Previs et al.   JOURNAL OF LIPID RESEARCH

Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters

(2011) Jose Castro-Perez et al.   JOURNAL OF LIPID RESEARCH

A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry

(2011) Michael E. Lassman et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Headspace analyses of acetone: A rapid method for measuring the 2H-labeling of water

(2010) Vinit Shah et al.   ANALYTICAL BIOCHEMISTRY

Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib

(2010) Laurent Yvan-Charvet et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

(2010) Evan A. Stein et al.   EUROPEAN HEART JOURNAL

Biochemical characterization of cholesteryl ester transfer protein inhibitors

(2010) Mollie Ranalletta et al.   JOURNAL OF LIPID RESEARCH

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

(2010) Eric J. Niesor et al.   JOURNAL OF LIPID RESEARCH

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanistic studies of blood pressure in rats treated with a series of cholesteryl ester transfer protein inhibitors

(2009) Michael DePasquale et al.   DRUG DEVELOPMENT RESEARCH

Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition

(2009) Xiao Hu et al.   ENDOCRINOLOGY

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

(2008) Daniel Bloomfield et al.   AMERICAN HEART JOURNAL

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

(2008) M J Forrest et al.   BRITISH JOURNAL OF PHARMACOLOGY

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

(2008) R Krishna et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS